Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from IRWD

3 High-Risk, High-Reward Penny Stocks to Buy

High-risk, high-reward stocks are highly favored by investors having high risk tolerance to achieve potential returns and yield. Hence, it could be ideal to buy fundamentally solid, high-risk, high-reward penny stocks Taboola.com (TBLA), Ironwood Pharmaceuticals (IRWD), and Castor Maritime (CTRM). Keep reading.

Buy These 3 Pharma Stocks in July

Buy These 3 Pharma Stocks in July

The pharmaceutical industry looks well-positioned for long term growth due to the globalization of the industry, increasing investments to develop life-saving drugs, rise in chronic diseases, and a rapidly aging population. To that end, it could be wise to buy fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Ironwood Pharmaceuticals (IRWD),…

3 Quality Medical Stocks to Explore

3 Quality Medical Stocks to Explore

The medical industry is envisioned to remain afloat and thrive in the foreseeable future, thanks to advanced medical discoveries. Therefore, quality medical stocks Amphastar Pharmaceuticals (AMPH), Ironwood Pharmaceuticals (IRWD), and Voyager Therapeutics (VYGR) could be wise portfolio additions now. Read on….

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

VectivBio Stock Catapults 39% After Ironwood Agrees To Buy It For $1 Billion

Ironwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock reversed higher.

Investors Business Daily

2 Pharma Stocks Investors Are Flocking

The pharmaceutical industry is expected to thrive amid robust demand and government support. Given the solid long-term prospects of the industry, investors should consider buying pharma stocks Ironwood Pharmaceuticals (IRWD) and Calliditas Therapeutics (CALT). Read on.

Ironwood Pharmaceuticals: Q1 Earnings Insights

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Ironwood Pharmaceuticals Q1 2022 Earnings Conference Call On May 5, 2022 At 08:30 AM ET

Ironwood Pharmaceuticals (NASDAQ:IRWD) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

inkl

Read news from The Economist, FT, and more,
with one subscription

2 Under-the-Radar Pharmaceutical Stocks to Add to Your Watchlist

2 Under-the-Radar Pharmaceutical Stocks to Add to Your Watchlist

Irrespective of worsening supply chain disruptions due to the Russia-Ukraine war, the pharmaceutical industry is expected to witness stable growth given the rising medical needs of an aging population and rapid advancements in the drug development process. So, amid an apparent resurgence of COVID-19 cases, we think it could be…

Ironwood Pharmaceuticals Earnings Perspective: Return On Capital Employed

Ironwood Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data Ironwood Pharmaceuticals (NASDAQ:IRWD) posted a 25.91% decrease in earnings from Q3. Sales, however, increased by 12.9% over the previous quarter to $117.13 million.

Ironwood Reports Mixed Q4 Results; Linzess Joins Blockbuster Club As US Sales Exceed $1B

Ironwood Reports Mixed Q4 Results; Linzess Joins Blockbuster Club As US Sales Exceed $1B

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD)

Recap: Ironwood Pharmaceuticals Q4 Earnings

Recap: Ironwood Pharmaceuticals Q4 Earnings

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q4 earnings results on Thursday, February 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

1

People

Dipanjan BanchurSince

Steve Reitmeister

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

Medical – Pharmaceuticals

Taro Pharmaceutical Industries Ltd

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

236,483 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play